AION Labs

A venture studio building AI companies to revolutionize drug discovery and development.

Incubator Active Rehovot, Israel Est. 2021
Visit website ↗ LinkedIn
Last updated 2026-07-20
Portfolio
1
in our dataset
Rounds participated
1
Rounds led
0
Rounds' value
$2.0M
total disclosed, rounds participated
Stages
Pre-Seed, A Round, Seed

About

AION Labs is an Israeli venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes. It was formed after winning a government tender in 2020 and officially launched in October 2021. AION Labs is a unique partnership backed by major companies in the pharmaceutical, technology, and investing sectors, including AstraZeneca, Merck KGaA, Pfizer, Teva Pharmaceuticals, Amazon Web Services (AWS), Israel Biotech Fund, Amiti Ventures, and BioMed X, with support from the Israel Innovation Authority. The venture studio aims to create and adopt groundbreaking AI technologies to transform drug discovery and development, ultimately improving health and patient outcomes globally. They work by identifying R&D challenges, assembling multidisciplinary teams of scientist-founders, and providing them with pre-seed funding, access to proprietary data, mentorship from pharma experts, and comprehensive company-building support. AION Labs has launched nine companies in over three years.

Portfolio · 1

OMEC.AI
Predicting Drug Success in Clinical Trials
1 round $2.0M committed Latest: 2022-09

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences8

Q&A

What is AION Labs' primary focus as an investor?
AION Labs is a venture studio focused on building and investing in startups that leverage AI to revolutionize drug discovery and development, primarily within the Health Tech & Life Sciences sector.
Which companies are among AION Labs' most recent portfolio additions?
In December 2024, AION Labs added Cassidy Bio, which raised $8M in Seed funding, and ProPhet, which secured $1M in Pre-Seed funding, to its portfolio.
Has AION Labs had any notable exits recently?
Yes, in January 2026, AION Labs saw an exit with the acquisition of CombinAble.AI by insitro.
What is AION Labs' investment stage preference?
AION Labs primarily invests in Pre-Seed, Seed, and A Round stages. According to startupim data, they have made 3 Pre-Seed investments and 4 Seed investments.
Who are the key executives at AION Labs?
The key executives at AION Labs include Mati Gill as CEO, Sharon Gour Arie as COO, and Dr. Yair Benita as CTO.
What is the geographic focus of AION Labs' operations?
AION Labs is headquartered in Rehovot, Israel, and is supported by the Israeli Innovation Authority.
Can you name another recent investment by AION Labs?
In August 2024, AION Labs invested in TenAces Biosciences, a Seed-stage company focused on Molecular Glue Therapeutics.
What kind of partners support AION Labs?
AION Labs operates as a unique partnership formed by AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures, and AWS, with support from the Israeli Innovation Authority.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)